Theoretical investigation of the derivatives of favipiravir (T-705) as potential drugs for Ebola virus

References

[1] Centers for disease controls and prevention. 2014. Outbreaks chronology: Ebola haemorrhagic fever. Available at: http://www.cdc.gov/vhf/ebola/. Accessed: Jan 2016.Search in Google Scholar

[2] Hayden E. The Ebola questions: scientists know a lot about the virus that causes Ebola — but there are many puzzles that they have yet to solve. Nature. 2014;514:554–7.10.1038/514554aSearch in Google Scholar PubMed

[3] Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med. 2014;371:1418–25.10.1056/NEJMoa1404505Search in Google Scholar PubMed

[4] http://www.who.int/mediacentre/news/releases/2016/ebola-zero-liberia/en/. Accessed: Dec 2016.Search in Google Scholar

[5] Ippolito G, Puro V, Piselli P. Ebola in West Africa: who pays for what in the outbreak? New Microbiol. 2015;38:1–3.Search in Google Scholar PubMed

[6] The Economist. Ebola’s legacy after the passing, The virus will have a long-lasting impact on already poor countries. 2015. Available at: http://www.economist.com/news/middle-east-and-africa/21637391-virus-will-have-long-lasting-impact-already-poor-countries-after. Accessed: Dec. 2016.Search in Google Scholar

[7] Zhang Y, Li H, Cheng A. Ebola haemorrhagic fever. In: Li H, editor. Radiology of infectious diseases: volume 1, Chapter 13. Dordrecht, Heidelberg, New York, London: Springer Science+Business Media Dordrecht and People’s Medical Publishing House, 2015.Search in Google Scholar

[8] Judson S, Prescott J, Munster V. Understanding Ebola virus transmission. Viruses. 2015;7:511–21.10.3390/v7020511Search in Google Scholar PubMed PubMed Central

[9] Mendoza EJ, Qiu X, Kobinger GP. Progression of Ebola therapeutics during the 2014–2015 outbreak. Trends Mol Med. 2016;22:164–73.10.1016/j.molmed.2015.12.005Search in Google Scholar PubMed

[10] Kaushik A, Tiwari S, Jayant RD, et al. Towards detection and diagnosis of Ebola virus disease at point-of-care. Biosens Bioelectron. 2016;75:254–72.10.1016/j.bios.2015.08.040Search in Google Scholar PubMed PubMed Central

[11] http://www.who.int/medicines/emp_ebola_q_as/en/. Accessed: Dec 2016.Search in Google Scholar

[12] Buttler D. Ebola drug trials set to begin amid crisis. Nature. 2014;513:156.10.1038/513013aSearch in Google Scholar PubMed

[13] Furuta Y, Takahashi K, Shiraki K, et al. T-705 (Favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82:95–102.10.1016/j.antiviral.2009.02.198Search in Google Scholar PubMed PubMed Central

[14] Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705) a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–54.10.1016/j.antiviral.2013.09.015Search in Google Scholar PubMed PubMed Central

[15] Furuta Y, Takahashi K. Inventors; Toyama Chemical Co., Ltd., assignee. Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both. CA2339272A1. 2 Mar 2000.Search in Google Scholar

[16] Shi F, Zongtao L, Kong, L, et al. Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide. Drug Discov Ther. 2014;8:117–20.10.5582/ddt.2014.01028Search in Google Scholar PubMed

[17] De Clercq E. Antivirals: past, present and future. Biochem Pharmocol. 2013;85:727–44.10.1016/j.bcp.2012.12.011Search in Google Scholar PubMed

[18] De Clercq E. Dancing with chemical formulae of antivirals: A personal account. Biochem Pharmocol. 2013;86:711–25.10.1016/j.bcp.2013.07.012Search in Google Scholar

[19] De Clercq E. Dancing with chemical formulae of antivirals: A panoramic view (part 2). Biochem Pharmocol. 2013;86:1397–410.10.1016/j.bcp.2013.09.010Search in Google Scholar

[20] Hernandes MZ, Cavalcanti SM, Moreira DR, et al. Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets. 2010;11:303–14.10.2174/138945010790711996Search in Google Scholar PubMed

[21] Kharkar PS, Ramasami P, Choong YS, et al. Discovery of anti-Ebola drugs: a computational drug repositioning case study. RSC Adv. 2016;6:26329–40.10.1039/C6RA01704ESearch in Google Scholar

[22] Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09, revision D.01. Wallingford CT: Gaussian, Inc, 2009.Search in Google Scholar

[23] Dooley R, Milfeld K, Guiang C, Pamidighantam S, Allen G. From proposal to production: lesson learned developing the computational chemistry grid cyberinfrastructure. J Grid Comput. 2006;4:195–208.10.1007/s10723-006-9043-7Search in Google Scholar

[24] Milfeld K, Guiang C, Pamidighantam S, Giuliani J. Proceedings of the 2005 Linux Clusters: The HPC Revolution, NCSA University of Illinois, CHPC University of New Mexico and IBM, 2005.Search in Google Scholar

[25] Dooley R, Allen G, Pamidighantam S. Proceedings of the 13th Annual Mardi Gras Conference, CCT. Baton Rouge, LA: Louisiana State University, 2005:83.Search in Google Scholar

[26] Brown CS, Lee MS, Leung DW, et al. In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol. 2014;426:2045–58.10.1016/j.jmb.2014.01.010Search in Google Scholar PubMed

[27] Morris GM, Goodsell DS, Halliday RS, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639–62.10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-BSearch in Google Scholar

[28] HyperChem(TM) Professional 7.51, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA.Search in Google Scholar

[29] Lien EJ, Guo Z-R, Li R-L, et al. Use of dipole moment as a parameter in drug-receptor interaction and quantitative structure-activity relationship studies. J Pharm Sci. 1982;71:641–55.10.1002/jps.2600710611Search in Google Scholar PubMed

[30] Shi F, Li Z, Kong L, et al. Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide. Drug Discov Ther. 2014;8:117–20.10.5582/ddt.2014.01028Search in Google Scholar PubMed

[31] Joseph T, Varghese HT, Panicker CY, et al. Vibrational spectroscopic investigations and computational study of 5-tert-Butyl-N-(4-trifluoromethylphenyl) pyrazine-2-carboxamide. Spectrochim Acta A. 2013;113:203–14.10.1016/j.saa.2013.04.101Search in Google Scholar

[32] Sakthivel S, Alagesan T, Al-Saadi AA, et al. Vibrational spectra of 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazine-2-carboxamide: combined experimental and theoretical studies. Spectrochim Acta A. 2014;127:157–67.10.1016/j.saa.2014.02.066Search in Google Scholar PubMed

[33] Lukose J, Panicker CY, Nayak PS, et al. Synthesis, structural and vibrational investigation on 2-phenyl-N-(pyrazin-2-yl)acetamide combining XRD diffraction, FT-IR and NMR spectroscopies with DFT calculations. Spectrochim Acta A. 2015;135:608–16.10.1016/j.saa.2014.07.004Search in Google Scholar PubMed

[34] Runge E, Gross EKU. Density-functional theory for time-dependent systems. Phys Rev Lett. 1984;52:997–1000.10.1103/PhysRevLett.52.997Search in Google Scholar

[35] Atkins PW, De Paula J. Atkins’ physical chemistry. Oxford: Oxford University Press; 2001.Search in Google Scholar

[36] Hoffmann R, Schleyer P, Schaefer HF. Predicting molecules—more realism, please!. Angew Chem Int Ed. 2008;47:7164–7.10.1002/anie.200801206Search in Google Scholar PubMed

[37] Smither SJ, Eastaugh LS, Steward JA, et al. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014;104:153–5.10.1016/j.antiviral.2014.01.012Search in Google Scholar PubMed